Co-Founder, Magellan Labs
Member and Former Chair of UNC Board of Trustees
Chair, Chancellor’s Innovation Circle
In 1991, Dr. Caudill and Dr. Alfred Childers co-founded Magellan Laboratories Incorporated, a pharmaceutical development company. Under their leadership Magellan grew to 600 people with 500 employees in RTP and 100 employees in San Diego. Magellan was recognized as one of the fastest growing, privately held companies in the Research Triangle area and received numerous regional and national awards for growth and entrepreneurial development. Magellan was awarded the Triangle Business Journal’s Fast 50 award for nine years and was in the Top 10 for six of the nine years. In 1998, Drs. Caudill and Childers were named Entrepreneur of the Year for North and South Carolina by Ernst and Young, The Kauffman Foundation, USA Today, and NASDAQ and were Finalists for the 1998 National Entrepreneur of The Year. They received two awards from the North Carolina Council for Entrepreneurial Development (CED), the 2002 Entrepreneurial Excellence Award and the 2002 Deal of the Year Award.
In April 2002, Magellan Laboratories Incorporated was acquired by Cardinal Health. Dr. Caudill and Dr. Childers became co-presidents of Pharmaceutical Development for Cardinal Health. They led over 1400 employees in nine sites including Research Triangle Park NC, San Diego CA, Somerset NJ, Philadelphia PA, Manchester UK and Schorndorf GER and retired from Cardinal Health in December 2003. Dr. Caudill was Chair of the UNC-CH Board of Trustees from 2013-15. He is the Chair of the Chancellor’s Innovation Circle and is the Chair of the Executive Board of The Educational Foundation. He is co-chair of the current UNC Capital Campaign, was a Steering Committee member of the $2.4 billion Carolina First Campaign and was chair of the Private Fundraising Steering Committee for the UNC-CH Physical Science Complex. He is an Adjunct Professor of Chemistry at the UNC-CH and a member of the UNC-CH Chemistry Department External Advisory Board. He is a member of the Advisory Working Group for the UNC-CH Entrepreneurship Minor and is Chair of the Private Fundraising Campaign for the Entrepreneurship Minor. He is a member of the Board of Visitors for Lineberger Comprehensive Cancer Center and a member of the Board of Directors for the Carolina Research Venture Fund. In 2008, he received the Distinguished Alumnus Award from UNC-CH, in 2013, was inducted into the Order of the Golden Fleece at UNC-CH and in 2014, received the Distinguished Service Medal from the UNC CH General Alumni Association.
In the spring of 2007, Professor Holden Thorp and he created and taught the Scientific Ventures course for the UNC-CH Entrepreneurship Minor. In the spring semesters of 2008 through 2014, he co-taught the Scientific Ventures course with Professor Joe DeSimone and in 2015 through 2016, he co-taught with Professor Greg Copenhaver. He co-taught the Minor’s Introduction to Entrepreneurship course from 2007 through 2014. He helped create and co-taught the UNC-CH Chancellor’s Faculty Entrepreneurship Bootcamp from 2009 through 2016. Dr. Caudill is an active entrepreneur and supporter of entrepreneurial endeavors. He served on the Advisory Board of Southern Capitol Ventures, served on the Life Sciences Advisory Board of the Aurora Funds and was a member of the Tri-State Investment Group. He is an investor in and former chairman of the Board of Directors of Liquidia Technologies Incorporated. He is currently chair of Purcado Incorporated.
Dr. Caudill received his B.S. degree in Chemistry at the University of North Carolina at Chapel Hill with undergraduate research under the direction of Professor Royce Murray. In 1983, Dr. Caudill received his doctorate in Analytical Chemistry from Indiana University under the direction of Professor R. Mark Wightman. Upon graduation, he became a research scientist at Baxter-Travenol. In 1987, he joined the Glaxo Research Institute where he played a major role in the establishment of the Analytical Chemistry Department in the Research Triangle Park in NC. Currently marketed product lines which his groups helped develop include Zantac, Imitrex, Zofran, Zinacef, and Ventolin.